Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 4,241 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune Deficiency Disorder Clear all

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS), pH 7.0; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 42
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more

Conditions: HIV Infections
Interventions: SAIA-HIV-SSP; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Suicidal Ideation and Behavior, HIV, AIDS (Acquired Immune Deficiency Syndrome)
Interventions: AI-DBT; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Newark, New Jersey

Conditions: HIV Infections
Interventions: Alovudine; Drug
Lead sponsor: Lederle Laboratories; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: Aldesleukin, HAART; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Atovaquone, Pentamidine isethionate; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Berkeley, California • Harbor City, California • Los Angeles, California + 12 more

Conditions: HIV/AIDS, Chronic Pain
Interventions: Acceptance and Commitment Therapy (ACT), Chronic Pain Education; Behavioral · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 50 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: Cyclosporine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 12
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 7 more

Conditions: Severe Combined Immunodeficiency Disease, X-linked
Interventions: CL20-i4-EF1α-hγc-OPT, Busulfan, CliniMacs; Genetic · Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 24 Months · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2034
U.S. locations: 3
States / cities: San Francisco, California • Memphis, Tennessee • Seattle, Washington

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Itraconazole; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Toxoplasmosis, Cerebral, HIV Infections
Interventions: Azithromycin, Pyrimethamine, Leucovorin calcium; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Los Angeles, California • Miami, Florida • Worcester, Massachusetts + 5 more

Conditions: HIV Infection
Interventions: Patient Mentor Intervention, HIV transmission risk reduction; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: HIV-1 DNA vaccine with protein vaccine boost; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Lymphatic Disease, HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 22
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 16 more

Conditions: Hiv, Mental Health Issue, Support, Family
Interventions: MPowerment PrEP Promotion Intervention; Behavioral
Lead sponsor: George Mason University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: HIV Infection, Advanced End Stage Heart Failure
Interventions: HIV-positive heart transplant; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: AS-101; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections, Pneumococcal Infections
Interventions: 13-valent pneumococcal conjugate vaccine, Blood draw; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: HIV/AIDS
Interventions: WISH Adherence, WISH Parenting; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 16 Years and older · Female only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: Hepatitis C, HIV Infections
Interventions: Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Cincinnati, Ohio • Richmond, Virginia

Conditions: Pompe Disease
Interventions: Observational; Other
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: Adefovir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Facial Lipoatrophy
Interventions: SCULPTRA (poly-L-lactic acid injection); Device
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Horsham, Pennsylvania

Search by objective public record fields.

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

A Systems Analysis and Improvement Approach for Optimizing HIV Service Delivery in Syringe Services Programs

HIV Suicide Prevention With AI-DBT

A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole

Acceptance and Commitment Therapy for Aging People Living With HIV in Chronic Pain

A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease

Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS

Test of an Intervention to Improve HIV Care

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

PrEP Intervention in Prince George's County, Maryland

HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients

A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

A Peer-Led Intervention to Improve Postpartum Retention in HIV Care

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.

Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)

A Study of Patients Who Recently Have Been Infected With HIV